Member of the Board of Directors of ChemoMetec A/S since October 2021. Re-elected in 2024.
Member of the Audit, Nomination and Remuneration Committees.
Not independent as per the definitions of the corporate governance recommendations of Nasdaq Copenhagen, as the law firm of which Niels Thestrup is a partner provides legal advice to ChemoMetec.
Position
Attorney-at-law (SC), Partner, Kønig Advokater I/S. CEO of Thestrup Holding Advokatanpartsselskab, Thestrup Advokatanpartsselskab, N. Thestrup Holding ApS, Thestrup Ejendomme ApS and Ziegler Holding ApS.
Directorships
Chairman of the boards of directors of Co-Ros Fond, Nova5 Arkitekter a/s, Sani Membranes A/S, Løvbjerggård A/S, KG Holding, Søllerød ApS, Pnn Medical A/S, Pnn Medical US A/S, Pnn Memocore ApS and A/S Erik Thestrup. Member of the boards of directors of MedTech Invest A/S, Ejendomsselskabet Dr. Tværgade 5 A/S, Brancor Futures A/S Brancor Securities A/S.
Areas of expertise
Commercial law, including capital markets law, general corporate governance, economics and international business affairs.
Member of the Board of Directors of ChemoMetec A/S since October 2013. Re-elected in 2024.
Member of the Board of Directors of ChemoMetec A/S for the period 2001-2010.
Not independent as per the definitions of the corporate governance recommendations of Nasdaq Copenhagen, as Martin Glensbjerg has been a senior employee of ChemoMetec within the past five years.
Position
Senior advisor of ChemoMetec A/S and co-founder of ChemoMetec A/S. CEO of ChemoMetec Holding A/S and HMG Technology ApS.
Directorships
Member of the boards of directors of ChemoMetec Holding A/S, Sani Membranes A/S, Udviklingsselskabet Hovedgaden 148 ApS and Byggeselskabet Danmark A/S.
Areas of expertise
Product development and project management as well as production and business development.
Member of the Board of Directors of ChemoMetec A/S since October 2020. Re-elected in 2024.
Chairman of the Nomination Committee and Member of the Audit Committee.
Independent as per the definitions of the corporate governance recommendations of Nasdaq Copenhagen.
Position
Project Director, Data Science, Novo Nordisk A/S.
Areas of expertise
Experience in research and development, broad expertise in biology, and in-depth knowledge of the activities and challenges of the principal customer group that ChemoMetec targets.
Member of the Board of Directors of ChemoMetec A/S since October 2021. Re-elected in 2024.
Chairman of the Audit Committee and Member of the Nomination Committee.
Independent as per the definitions of the corporate governance recommendations of Nasdaq Copenhagen.
Position
Professional board member.
Directorships
Chairman of Statens It-råd, Member of the boards of directors of the ATTA, Foundation and Center for Cyberkompetencer
Areas of expertise
Broad knowledge of national and international business affairs, strategic and business development, digitalization, and general management.
Member of the Board of Directors of ChemoMetec A/S since October 2014. Re-elected in 2024.
Chairman of the Remuneration Committee and Member of the Nomination Committee.
Independent as per the definitions of the corporate governance recommendations of Nasdaq Copenhagen.
Position
Director and co-owner of telecommunications provider DSTNY A/S and CEO of Jore ApS, Soft Invest Holding ApS, Bulltrading ApS, PRE Invest Holding ApS, and Soft Holding ApS.
Directorships
Member of the boards of directors of Leto Leasing P/S and BPM Micro ApS.
Areas of expertise
Strategic and business development, general corporate governance, specifically sales and marketing.